Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Addition...
March 22 2019 - 4:01PM
Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated
to bringing biotech ingenuity to medical dermatology by delivering
differentiated, new therapies to the millions of patients living
with chronic skin conditions, today announced the closing of its
previously announced underwritten public offering of 11,283,019
shares of its common stock, including 1,471,698 shares sold upon
full exercise of the underwriters’ option to purchase additional
shares of common stock, at a price to the public of $13.25 per
share. All of the shares were sold by Dermira. The aggregate gross
proceeds to Dermira from the offering, before deducting the
underwriting discounts and commissions and offering expenses, were
approximately $149.5 million.
Citigroup, Cowen, Cantor Fitzgerald & Co. and Guggenheim
Securities acted as book-runners for the offering. Needham &
Company and H.C. Wainwright & Co. acted as co-managers.
The public offering was made pursuant to a shelf registration
statement on Form S-3 that was filed by Dermira with the Securities
and Exchange Commission (“SEC”) on November 7, 2018 and was
declared effective on November 21, 2018. This offering was
made solely by means of a prospectus supplement and accompanying
prospectus relating to and describing the terms of the offering,
copies of which may be obtained from Citigroup Global Markets Inc.,
c/o Broadridge Financial Solutions, Attention: Prospectus
Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by
telephone at 800-831-9146; Cowen and Company, LLC, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717,
or by telephone at 631-274-2806; Cantor Fitzgerald & Co.,
Attention: Capital Markets, 499 Park Avenue, 6th Floor, New York,
NY 10022, or by email at prospectus@cantor.com; and Guggenheim
Securities, LLC, Attention: Equity Syndicate Department, 330
Madison Avenue, 8th Floor, New York, NY 10017, by telephone at
212-518-9658, or by email at
GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy Dermira’s common stock, nor shall
there be any sale of Dermira’s common stock in any state or
jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
Contacts:Media: Erica JeffersonVice President,
Corporate Communications650-421-7216media@dermira.com
Investors:Ian Clements, Ph.D.Vice President, Investor
Relations650-422-7753investor@dermira.com
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jul 2023 to Jul 2024